SUPPLEMENTAL METHODS
ZL0580 Synthesis (4-Nitrophenyl) sulfonyl)-L-proline (2).
To a solution of methyl ((4-nitrophenyl) sulfonyl)-L-prolinate (1) (500 mg, 1.6 mmol) in 16 mL CH3OH, LiOH·H2O (334 mg, 8 .0 mmol) in 8 mL H2O was added. The mixture was allowed to stir at room temperature for 4 hours. After concentration, the solution was acidified by 10% HCl to pH = 3 and extracted by dichloromethane (DCM) to obtain 2 (540 mg, quant.) as a white solid.
The crude product was used directly in the next step.
(S)-1-((4-Nitrophenyl) sulfonyl)-N-phenylpyrrolidine-2-carboxamide (3).
To a solution of 2 (100 mg, 0.33 mmol) and aniline (31 mg, 0.33 mmol) in 5 mL of DCM, HBTU (321 mg, 1.0 mmol) and DIPEA (295 µL, 1.67 mmol) were added. After stirring at rt. overnight, the mixture was extracted with DCM (20 mL × 3). The organic layer was washed with 1 N NaHSO4 (aq.), saturated NaHCO3 (aq.), brine and dried over anhydrous Na2SO4. The resulting solution was evaporated, and the residue was purified by PTLC (DCM/MeOH = 70:1) 
ZL0580
Reagents and conditions: (a) LiOH, CH 3 OH/H 2 O, rt., 4 h, quant.; (b) aniline, HBTU, DIEA, DCM, rt., 66%; (c) Zn, NH 4 Cl, EtOH/H 2 O, reflux; (d) 1-isocyanato-4-(trifluoromethyl)benzene, DCM, rt., 66% for two steps. δ 168. 94, 150.48, 141.93, 137.12, 129.04, 128.97, 124.85, 124.55, 120.20, 120.10, 62.91, 49.85, 30.36, 24.49 .
(S)-1-((4-Aminophenyl) sulfonyl)-N-phenylpyrrolidine-2-carboxamide (4).
To a solution of 3 (70 mg, 0.19 mmol) in 10 mL CH3CH2OH, NH4Cl (50 mg, 0.93 mmol) in 3 mL H2O and Zn dust (123 mg, 1.9 mmol) were added. The solution was allowed to reflux for 0.5 hour. Then it was filtered, and the filtrate was extracted by DCM for three times. The organic layer was dried and concentrated to give 4 as a white foam which was used directly in the next step.
(R)-N-Phenyl-1-((4-(3-(4-(trifluoromethyl) phenyl) ureido)phenyl)sulfonyl)pyrrolidine-2-carboxamide (ZL0580).
To a solution of 4 (0.187 mmol) in 5 mL DCM, 1-isocyanato-4-(trifluoromethyl) benzene (37 mg, 0.2 mmol) was added. After stirring at rt. overnight, the mixture was concentrated and purified by PTLC (DCM/CH3OH = 50 :1) to give ZL0580 (65 mg, 66% for two steps) as a white 152.67, 144.19, 142.52, 137.74, 129.56, 128.81, 128.42, 125.75, 125.70, 124.32, 120.44, 118.35, 118.21, 62.61, 49.37, 30.83, 24.31 . HR ESI-MS (M + Na) + m/z = 555.1282 (calcd for C25H24F3N4O4SNa: 555.1290).
Compound binding analysis (TR-FRET)
384 well plate-based commercial TR-FRET Assay kits (Cayman Chemical, Ann Arbor, Michigan) were used to determine the binding affinity of ZL0580 to the bromodomains (BDs) of BRD4, BRD2, BRD3, and BRDT as well as CBP by time-resolved fluorescence energy transfer (TR-FRET) assays. A series of concentrations of the compound from 0.01 nM to 100 µM were added into a 384 well test plate and mixed with other reaction components based on the instructions from vendor followed by incubation 1h at room temperature. The commercially available BET inhibitor JQ1 was used as the control. The plates were read in time-resolved format by exciting the sample at 340 nm and reading emissions at 620 and 670 nm, using a 100 µs delay and a 500 µs window at a Tecan M1000 pro reader. A plot of the TR-FRET ratio (670 nm emission/620 nm emission versus inhibitor concentration on semi-log axes results in a sigmoidal dose-response curve typical of competitive assays. These data were further calculated out with the IC50 values of the tested compounds to the bromodomains. IC50 values are reported as the mean derived from three independent measurements. Each one is generated from at least 8 different concentrations.
PCR quantification of cell-associated HIV DNA and RNA
To quantify cell-associated HIV DNA in normal PBMCs, Total DNA was extracted from cells Table S5 . PCR reactions were performed in duplicate. Mean Ct values were used. HIV Gag and 3'-LTR copy numbers were normalized to GAPDH and calculated using the 2 -∆∆Ct method.
Establishment of Ultra-sensitive nested PCR for HIV production in supernatants
Ultrasensitive two-step nested PCR was established using a similar protocol as described (1).
First, to generate an HIV Gag standard curve, Gag gene was cloned into plasmid. Viral RNA was extracted from HIV-1 and cDNA was synthesized. Gag gene was amplified using the same PCR conditions as described above and the Gag-Out-F/R primers ( Table S5) . Gag PCR products were gel purified using a Zymoclean Gel DNA Recovery Kit (Zymo) and cloned into pGEM-T Easy Vector Systems (Promega). Cloned plasmids were prepared and the concentrations were calculated as copy/µl by using an online tool (http://scienceprimer.com/copy-number-calculatorfor-realtime-pcr). Plasmids were serially diluted ten-fold from 10 6~1 0 0 copies and subjected to the first round PCR for amplification (16 cycles), followed by a second-round of nested PCR for 40 cycles by using Gag-F/R primers and the CFX Connect Real-Time PCR Detection System (Bio-Rad). Primer sequences for the first-round and second-round PCRs were shown in Table   S5 . A standard curve was generated based on Cq values of the nested PCR and plasmid copies.
CRISPR/Cas9 knockout of BRD4 and BRD2
Guide RNA sequences were cloned into lentiCRISPR v2 vector (a gift from Dr. 
Western Blotting (WB)
Protein expression in WT or Gene-KO J-Lat cells was measured by WB. Briefly, following experimental treatments, cells were harvested, washed and then lysed in NP-40 cell lysis buffer (Thermo Fisher Scientific) that contains 20 mM Tris-HCl, 0.15mM of NaCl, 0.2mM EDTA, 1% NP40, protease inhibitor cocktail (Sigma p8340), and 1mM PMSF. Cells were lysed in the lysis buffer by rotation at RT for 1 hour. Cell lysates were centrifuged at 4°C and the supernatants were collected, followed by measurement of total protein concentration using Microplate BCA Protein Assay Kit (Pierce™, Thermo Fisher Scientific). 20 µg proteins were separated using SDS-PAGE gel and then transferred to an Immuno-Blot PVDF Membrane. The membrane was blocked (5% skim milk powder in TBST) and then incubated with individual protein-specific primary antibodies as described in the Methods of the paper. Primary antibody incubation was conducted overnight at 4°C. After washing three times in TBST, the membrane was incubated with secondary anti-rabbit or anti-mouse IgG-HRP (Thermo Fisher), depending on the primary antibody used. The membrane was incubated in Super Signal West Pico Chemiluminescent Substrate (Thermo Fisher) and the results were captured. Molecular weights of target proteins
were assessed by comparison with molecular weight markers.
Chromatin immunoprecipitation (ChIP)-qPCR
About 15 × 10 6 J-Lat cells were transferred to 6-well plate and treated accordingly as described in the Main Text. Cells were harvested and washed. Cell pellets were re-suspended in 10ml PBS buffer and fixed with 37% formaldehyde to cross-link DNA and proteins. The fixation reaction was stopped by adding 1.1ml of 10x Glycine for 5 min at RT. Cells were centrifuged and the supernatants were removed, followed by re-suspension of cells in ice-cold Lysis Buffer on ice for 30 min. Cells were centrifuged at 5,000 rpm for 10 min to pellet the nuclei. Nuclei pellets were re-suspended in 700µl shearing buffer plus 3.2µl of PIC and 3.2µl of PMSF, and were then sonicated using the determined conditions. Sheared chromatin samples were used to set up ChIP reactions by adding the magnetic beads and 5 µg of anti-Tat (1mg/ml) (MA1-71509; Thermo Fisher), Anti-BRD4 (E2A7X) (13440, Cell Signaling) or control mouse IgG (2.5mg/ml) (Cell Signaling) for overnight rotation at 4°C. Following multiple washes with ChIP buffers, the chromatin was reverse cross-linked and treated with proteinase K. The eluted DNA was further purified by phenol-chloroform extraction and used in performance of real time PCR. The primer sequences used in CHIP-qPCR for HIV 5'-LTR and GAPDH promoter are shown in Table S5 .
The results were analyzed by the fold enrichment method with the formula % enrichment = 2− (CT IP − CT mock).
MNase Nucleosomal Mapping
Following treatments, J-Lat cells were cross-linked using the same method as described in the CHIP assay. Cells were then washed with 1ml buffer B (0.25% Triton-X 100, 1 mM EDTA, 0.5 mM EGTA, 20 mM Herpes, pH 7.6) and 1ml buffer C (150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM Herpes, pH 7.6). Following one wash in cold PBS, ~15 x 10 6 cross-linked cells were suspended in 1ml buffer A (300 mM sucrose, 2 mM Mg acetate, 3 mM Cacl2, 10 mM Tris pH 8.0, 0.1% Triton X-100, 0.5 mM DTT), incubated on ice for 5 min, and then dounced with 2ml dounce grinders (Tight Pestle, Kontes) for 20 times. Nuclei were collected by centrifuging at 4°C, 750 x g for 5 min. Pellets were washed twice in 1ml buffer D (25% glycerol, 5 mM Mg acetate, 50 mM Tris pH 8.0, 0.1 mM EDTA, 5 mMDTT) at 15 x 10 6 nuclei/ml. Chromatin was collected by centrifuging at 4°C, 750xg for 5 min. The pellets were suspended in 1ml buffer MN (60 mM KCl, 15 mM NaCl, 15 mM Tris pH 7.4, 0.5 mM DTT, 0.25 mM sucrose, 1.0 mM CaCl2) at 1.5 x 10 7 nuclei/ml. 150µl aliquots (2.25 x 10 6 nuclei) were treated with 0, 0.5, 5, 20, 50, or 500 U/ml of MNase (USB) for 30 min at 37°C. Reactions were stopped by addition of EDTA (12.5 mM) and SDS (0.5%). After 4 hours of proteinase K digestion at 37°C, each reaction was processed similar to that in ChIP assay from the point of DNA elution. After measuring concentrations, digested and undigested DNA samples were diluted to the same concentration (5 ng/µl) and used for real-time qPCR analysis. Fold change was calculated using delta CT method and the ratio of the amount of digested DNA to the undigested DNA for each primer was calculated.
SUPPLEMENTAL FIGURES
Figure S1 µM). Cell viability was measured by flow cytometry as described above on Day 6 after treatment (on the day when intracellular p24 was examined by FACS in Fig. 2E-F ). * p<0.05; ** p<0.005. (A-C) Normal human PBMCs (n=3) were activated with PHA for 2 days and treated with ZL0580 (8µM) (PHA/ZL0580) or not (PHA alone) for 3 days (as described in Figure 2A ). the second round ultra-sensitive nested PCR for 40 cycles using the primers Gag-F/R ( Table S5 ).
The standard curve was generated according to the Cq values of the nested real-time PCR. Table S5 . Primer sequences for Q-PCR quantification of HIV DNA/RNA and CHIP-qPCR analysis Primers Sequence Gag-F 5′-GGAAGCTGCAGAATGGGATA-3′ Gag-R 5′-GCTATGTCACTTCCCCTTGG-3′ Gag-out-F 5′-GAGCCACCCCACAAGATTTA-3′ Gag-out-R 5′-AGGGTTCCTTTGGTCCTTGT-3′ 3'LTR-F 5′-CAGATGCTGCATATAAGCAGCTG-3′ 3'LTR-R 5′-TTTTTTTTTTTTTTTTTTTTTTTTTTGAAG-3′ CHIP promotor region 5' LTR-F 5′-GTTAGACCAGATCTGAGCCT-3′ 5' LTR-R 5′-GTGGGTTCCCTAGTTAGCCA-3′ GAPDH-CHIP-F 5′-CCACATCGCTCAGACACCAT-3′ GAPDH-CHIP-R 5′-CCCGCAAGGCTCGTAGAC-3′ Table S6 . Guide RNA sequences for BRD4 and BRD2 CRISPR/Cas9 knockout Primers Sequence BRD2-gRNA 5′-GCATTGATGCAACCTTCTGTAGG-3′ BRD4-gRNA 5′-TTCAGCTTGACGGCATCCACAGG-3′
